XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3
COMMITMENTS AND CONTINGENCIES
9 Months Ended
Sep. 30, 2024
COMMITMENTS AND CONTINGENCIES.  
COMMITMENTS AND CONTINGENCIES

9.    COMMITMENTS AND CONTINGENCIES

The Company is obligated under a license agreement with Advanced NeuroRehabilitation, LLC to pay a 4% royalty on net revenue collected from the sale of devices covered by the patent-pending technology. During the three and nine months ended September 30, 2024 and 2023, the Company recorded royalty expense from the sale of devices of

approximately $1 thousand and $13 thousand, $5 thousand and $19 thousand, respectively, in its Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss.